Ovarian clear-cell carcinoma is a cancer characterized by inherent resistance to platinum-based therapies and lacks an effective targeted therapeutic approach. On the other hand, chaperone-mediated autophagy is a lysosomal degradation mechanism to stabilize cellular homeostasis during stressful scenarios, but its role in modulating platinum response in ovarian cancer is not well understood.
Researchers in Korea have investigated the interaction of SET-domain containing 1B (SET1B) with other proteins in vitro, as well as the impact of SET1B depletion in hepatocellular carcinoma cell lines.
The majority of epilepsies are developmental disorders that start in childhood. But there is a large minority that starts in late adulthood. And increasingly, researchers are suspecting that such epilepsies share mechanisms with dementia. Summarizing the highlights of epilepsy research presented at the recent Annual Congress of the European Academy of Neurology (EAN), Aleksandar Ristic told his audience that the biggest epilepsy story out of the Congress was “not a drug, but it was a reframing.”
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s architecture is shaped through the organization of tissues, the establishment of molecular pathways, and the coordination of signals that will later sustain the body as an integrated system. It is likely the most delicate stage of life, where any disturbance in that foundational process can have lasting consequences on health.
At the 2026 World Congress of Neuropsychopharmacology (CINP), held in Glasgow June 26-29, 2026, researchers from Japan’s National Center of Neurology and Psychiatry (NCNP) showcased how human organoid technologies are reshaping the study of neurodevelopmental vulnerability, addiction and psychiatric disorders.
Gensci-134 (Genescience Pharmaceuticals Co. Ltd.) is a growth hormone receptor (GHR) agonist fusion protein that mimics the biological activity of growth hormone (GH), does not contain GH sequence and selectively activates human GHR for the treatment of GH deficiency (GHD). It is designed to enable once-every-4-week dosing.
Genescience Pharmaceuticals Co. Ltd. has been developing an SLC6A19 inhibitor – Gensci-144 – for the potential treatment of chronic kidney disease (CKD).
The gut microbiota may be altered in people with depression as a result of treatment. These microorganisms reorganize differently in individuals who respond to therapy. In a multiomics study of antidepressant-naive patients presented at the 2026 World Congress of Neuropsychopharmacology (CINP), scientists from National Taiwan University found that patients who improved after antidepressant treatment maintained a more balanced and functional microbial ecosystem, recovered beneficial metabolites, and displayed blood-based biological signals that aligned with these changes.
Graves’ disease is a form of autoimmune hyperthyroidism where the main extrathyroidal feature is thyroid eye disease. Autoantibodies that stimulate thyroid-stimulating hormone receptor (TSHR) are released and orchestrate hormone production in the thyroid tissue and the orbit. Regeneron Pharmaceuticals Inc. has developed REGN-24493, a monoclonal antibody (MAb) that binds TSHR and blocks its activation by those autoantibodies.
Hypoparathyroidism is a rare disorder characterized by low levels of parathyroid hormone (PTH) that lead to low blood calcium levels and hyperphosphatemia. Septerna Inc. is developing a small-molecule PTH1 receptor (PTH1R) agonist, SEP-479, designed to replace PTH and normalize serum calcium.
RSS
